Weekly nab-Paclitaxel+Carboplatin with Radiotherapy as First Line Therapy in Patients with Advanced Non-Small-Cell Lung Cancer

UMIN ID: UMIN000031017

Registered date:24/01/2019

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: Non-Small-Cell Lung Cancer
• Date of first enrollment: 2013/12/01
• Target sample size: 25
• Countries of recruitment: Japan
• Study type: Interventional
• Intervention(s): Weekly nab-Paclitaxel+Carboplatin with Radiotherapy

Outcome(s)

• Primary Outcome: The complete resection rate
• Secondary Outcome: 2 years no relapse survival rate and progression free survival rate for 2 years.

Key inclusion & exclusion criteria

• Age minimum: 20years-old
• Age maximum: 79years-old
• Gender: Male and Female
• Exclude criteria: 1) Taxane and CBDCA are contraindicated for administration. 2) A history of severe drug sensitivity. 3) A history of hypersensitivity to albumin. 4)Interstitial pneumonia or pulmonary fibrosis apparent in chest radiography. 5) Active or duplicated cancer with metachronous or simultaneous, multiple cancers. 6) Pleural effusion, drainage and pericardial effusion required drainage. 7) Have serious complications. 8) Patients with peripheral neuropathy of Grade 2 or higher. 9) HBs antigen positive 10) Pregnant women or women who may be pregnant. 11) A man who is willing to conceive. 12) The doctor in charge judged unsuitable for registration of this exam.

Related Information

• Primary Sponsor: University of Fukui Faculty of Medical Sciences
• Source(s) of Monetary Support: University of Fukui Faculty of Medical Sciences